International Conference on BREAST CANCER J Clin Exp Oncol 2018, Volume:7 DOI: 10.4172/2324-9110-C6-024

December 03-04, 2018

ANNUAL BIOPROCESSING OF Dubai, UAE ADVANCED CELLULAR THERAPIES CONGRESS

Electrochemotherapy, an innovative therapy for cancer breast: A case report of cancer breast with recurrence treated with a palliative intent

Ashok Mathew, Subathra Muthukumar, Mallika Tiruvadanant and S Sasi Kumar Lakshmi pain and palliative care clinic, India

lectrochemotherapy is a new method for the local treatment of cutaneous and subcutaneous metastases. Permeabilization of the cell membrane by electric pulses allows chemotherapy drugs like bleomycin to enter into the cell, increasing the possibility of cytotoxicity. Where other standard treatments are no longer possible, electrochemotherapy can be used effectively for local tumour control. Repeated use of electrochemotherapy has allowed for an increase in the rate of complete remissions. ECT is proposed, with a palliative intent, for skin and subcutaneous tumours. We investigated ECT for the treatment with a palliative intent of a small recurrent cancer of the breast with lymph node involvement, after neoadjuvant radiotherapy, in a patient with severe comorbidities who underwent both major mastectomy surgery and even local lymph node excision.

Background: Nevertheless, some patients recurrences, and chemotherapy has resulted in poor complete responses. It often leads to ulceration, bleeding, pain, sometimes maggot's formation. The quality of life is significantly reduced. Electrochemotherapy is a new method for the local treatment of cutaneous and subcutaneous metastases. Permeabilization of the cell membrane by electric pulses allows bleomycin to enter into the cell, increasing the possibility of cytotoxicity. Standard treatments are no longer possible; electrochemotherapy can be used effectively for local tumour control. Repeated use of electrochemotherapy has allowed for an increase in the rate of complete remissions. In fact, in 2013, this form of treatment, which consists of a low-dose cytostatic and electroporation, was also included in the mammary guidelines of the Working Group for Gynaecological Oncology (AGO) and the German Cancer Society (DKG).

dr.mathew.palliativecare@gmail.com